The Clinical Significance of Monitoring Homocysteine Levels in Peripheral Blood of Advanced Non-small Cell Lung Cancer Patients during Gemcitabine with Cis-platinum Program of Chemotherapy_West China Medical Journal

Authors：

 LiJun , ChenFang , LuPing , YangMei

Department of Laboratory Medicine, the Second People's Hospital of Jiangyou, Jiangyou, Sichuan 621701, P. R. China;

Corresponding?author：

Keywords：

Non-small cell lung cancer; Homocysteine; Chemotherapy; Gemcitabine with cis-platinum chemotherapy; Evaluation of therapeutic effect

DOI：

10.7507/1002-0179.201600376

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the alteration of serum homocysteine (Hcy) levels of advanced non-small cell lung cancer (NSCLC) patients during gemcitabine with cis-platinum (GP) program of chemotherapy and to explore the clinical value of monitoring Hcy in evaluating chemotherapy curative effect. Methods A total of 49 advanced NSCLC patients (including 28 squamous carcinoma and 21 adenocarcinoma) first treated between May 2012 and April 2015 were selected. The Hcy, cytokerantin-19-fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) levels of the morning fasting venous blood were measured before the first and after the second cycle of chemotherapy. Combined the pathological types of NSCLC, statistical analysis was carried out on the test results. Results All of the 49 patients completed two cycles of GP chemotherapy, and the chemotherapy was effective on 31 and ineffective in 18. Before the chemotherapy, the differences in the positive rates of Hcy, CYFRA21-1, and CEA were statistically significant respectively between squamous carcinoma and adenocarcinoma patients (P < 0.05). But when combined the two types, the differences of three indicators's positive rates were not significant (P > 0.05). After two cycles of GP chemotherapy, in the patients with effective chemotherapy, the Hcy, CYFRA21-1 and CEA levels were lower in both squamous carcinoma and adenocarcinoma patients compared with that before the chemotherapy; the difference in the decrease of Hcy levels in both of the two pathological types was significant (P < 0.05), while CEA levels was significant only in adenocarcinoma patients (P < 0.05) and CYFRA21-1 levels was significant only in squamous carcinoma patients (P < 0.05). Among the patients with ineffective chemotherapy, the Hcy, CYFRA21-1 and CEA levels increased compared with those before the chemotherapy; the difference in the increase of Hcy levels were significant in both of the two pathological types (P < 0.05), while CYFRA21-1 levels was significant only in squamous carcinoma patients (P < 0.05) and CEA levels was not significant in both of the two pathological types (P > 0.05). Conclusion The effect of chemotherapy and the pathogenetic condition can be assessed by monitoring serum Hcy levels of NSCLC patients during the chemotherapy.

Citation： LiJun, ChenFang, LuPing, YangMei. The Clinical Significance of Monitoring Homocysteine Levels in Peripheral Blood of Advanced Non-small Cell Lung Cancer Patients during Gemcitabine with Cis-platinum Program of Chemotherapy. West China Medical Journal, 2016, 31(8): 1380-1383. doi: 10.7507/1002-0179.201600376 Copy

1.	趙宇, 郭惠琴. NSCLC個體化治療研究進展[J].癌癥進展, 2011, 9(5):550-554.
2.	張秀亮, 王穎, 劉剛, 等.晚期非小細胞肺癌四種化療方案的最小成本分析[J].腫瘤學雜志, 2015, 21(8):645-650.
3.	唐丹.晚期非小細胞肺癌化療療效的臨床觀察[J].四川醫學, 2015, 36(10):1446-1448.
4.	王杰, 胡學寧, 陳大興.血清腫瘤標志物對晚期NSCLC放療療效的評估價值[J].實用癌癥雜志, 2014, 29(6):626-628.
5.	彭宇, 李崢, 熊艷麗, 等.晚期非小細胞肺癌不同含鉑兩藥方案一線化療預后因素的分析[J].第三軍醫大學學報, 2014, 36(16):1703-1708.
6.	Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98.
7.	Ozkan Y, Yardim-Akaydin S, Firat HA, et al. Usefulness of homocysteine as a cancer marker:total thiol compounds and folate levels in untreated lung cancer patients[J]. Anticancer Res, 2007, 27(2):1185-1189.
8.	Kohaar I, Kumar J, Thakur N, et al. Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population[J]. Biomarkers, 2010, 15(1):61-68.
9.	于秀艷, 王文龍, 吳雪峰, 劉曉峰.非小細胞肺癌患者血清葉酸、同型半胱氨酸和維生素B_(12)的檢測及其臨床意義[J].吉林大學學報:醫學版, 2015, 41(6):1235-1238.
10.	Hanagiri T, Sugaya M, Takenaka M, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stageⅠnon-small cell lung cancer[J]. Lung Cancer, 2011, 74(1):112-117.
11.	Cedrés S, Nu?ez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011, 12(3):172-179.
12.	李軍, 楊梅, 黃錦蓉.血清HCY、CYFRA21-1和CEA在晚期NSCLC患者化療療效評估中的臨床應用[J].現代檢驗醫學雜志, 2014, 29(1):147-149.
13.	夏紅安, 劉穎, 魯小龍.晚期非小細胞肺癌患者化療過程中監測外周血清同型半胱胺酸水平的臨床意義[J].國際檢驗醫學雜志, 2015, 36(16):2408-2409, 2411.
14.	魏凱, 黃毅超.血漿同型半胱氨酸、葉酸和維生素B12水平與非小細胞肺癌的關系[J].國際檢驗醫學雜志, 2012, 33(6):699, 701.
15.	Baltar VT, Xun WW, Johansson M, et al. A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk[J]. Eur J Epidemiol, 2013, 28(8):677-688.
16.	Cui LH, Yu Z, Zhang TT, et al. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC[J]. Pharmacogenomics, 2011, 12(6):797-808.

1. 趙宇, 郭惠琴. NSCLC個體化治療研究進展[J].癌癥進展, 2011, 9(5):550-554.
2. 張秀亮, 王穎, 劉剛, 等.晚期非小細胞肺癌四種化療方案的最小成本分析[J].腫瘤學雜志, 2015, 21(8):645-650.
3. 唐丹.晚期非小細胞肺癌化療療效的臨床觀察[J].四川醫學, 2015, 36(10):1446-1448.
4. 王杰, 胡學寧, 陳大興.血清腫瘤標志物對晚期NSCLC放療療效的評估價值[J].實用癌癥雜志, 2014, 29(6):626-628.
5. 彭宇, 李崢, 熊艷麗, 等.晚期非小細胞肺癌不同含鉑兩藥方案一線化療預后因素的分析[J].第三軍醫大學學報, 2014, 36(16):1703-1708.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98.
7. Ozkan Y, Yardim-Akaydin S, Firat HA, et al. Usefulness of homocysteine as a cancer marker:total thiol compounds and folate levels in untreated lung cancer patients[J]. Anticancer Res, 2007, 27(2):1185-1189.
8. Kohaar I, Kumar J, Thakur N, et al. Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population[J]. Biomarkers, 2010, 15(1):61-68.
9. 于秀艷, 王文龍, 吳雪峰, 劉曉峰.非小細胞肺癌患者血清葉酸、同型半胱氨酸和維生素B_(12)的檢測及其臨床意義[J].吉林大學學報:醫學版, 2015, 41(6):1235-1238.
10. Hanagiri T, Sugaya M, Takenaka M, et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stageⅠnon-small cell lung cancer[J]. Lung Cancer, 2011, 74(1):112-117.
11. Cedrés S, Nu?ez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011, 12(3):172-179.
12. 李軍, 楊梅, 黃錦蓉.血清HCY、CYFRA21-1和CEA在晚期NSCLC患者化療療效評估中的臨床應用[J].現代檢驗醫學雜志, 2014, 29(1):147-149.
13. 夏紅安, 劉穎, 魯小龍.晚期非小細胞肺癌患者化療過程中監測外周血清同型半胱胺酸水平的臨床意義[J].國際檢驗醫學雜志, 2015, 36(16):2408-2409, 2411.
14. 魏凱, 黃毅超.血漿同型半胱氨酸、葉酸和維生素B12水平與非小細胞肺癌的關系[J].國際檢驗醫學雜志, 2012, 33(6):699, 701.
15. Baltar VT, Xun WW, Johansson M, et al. A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk[J]. Eur J Epidemiol, 2013, 28(8):677-688.
16. Cui LH, Yu Z, Zhang TT, et al. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC[J]. Pharmacogenomics, 2011, 12(6):797-808.

West China Medical Journal

The Clinical Significance of Monitoring Homocysteine Levels in Peripheral Blood of Advanced Non-small Cell Lung Cancer Patients during Gemcitabine with Cis-platinum Program of Chemotherapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content